Prot #QBGJ398-301: A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PRO

Project: Research project

Project Details

StatusFinished
Effective start/end date10/2/20 → 10/2/23

Funding

  • PPD Investigator Services, LLC ((OE) Prot #QBGJ398-301 // (OE) Prot #QBGJ398-301)
  • QED Therapeutics, Inc. ((OE) Prot #QBGJ398-301 // (OE) Prot #QBGJ398-301)